keyword
MENU ▼
Read by QxMD icon Read
search

Simon turcotte

keyword
https://www.readbyqxmd.com/read/29914035/ketogenic-medium-chain-triglycerides-increase-brain-energy-metabolism-in-alzheimer-s-disease
#1
Etienne Croteau, Christian-Alexandre Castellano, Marie Anne Richard, Mélanie Fortier, Scott Nugent, Martin Lepage, Simon Duchesne, Kevin Whittingstall, Éric E Turcotte, Christian Bocti, Tamàs Fülöp, Stephen C Cunnane
BACKGROUND: In Alzheimer's disease (AD), it is unknown whether the brain can utilize additional ketones as fuel when they are derived from a medium chain triglyceride (MCT) supplement. OBJECTIVE: To assess whether brain ketone uptake in AD increases in response to MCT as it would in young healthy adults. METHODS: Mild-moderate AD patients sequentially consumed 30 g/d of two different MCT supplements, both for one month: a mixture of caprylic (55%) and capric acids (35%) (n = 11), followed by a wash-out and then tricaprylin (95%; n = 6)...
June 9, 2018: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/29688583/safe-use-of-proton-pump-inhibitors-in-patients-with-cirrhosis
#2
Rianne A Weersink, Margriet Bouma, David M Burger, Joost P H Drenth, S Froukje Harkes-Idzinga, Nicole G M Hunfeld, Herold J Metselaar, Margje H Monster-Simons, Sandra A W van Putten, Katja Taxis, Sander D Borgsteede
AIMS: Proton pump inhibitors (PPIs) belong to the most frequently used drugs, also in patients with cirrhosis. PPIs are extensively metabolized by the liver, but practice guidance on prescribing in cirrhosis is lacking. We aim to develop practical guidance on the safe use of PPIs in patients with cirrhosis. METHODS: A systematic literature search identified studies on the safety (i.e. adverse events) and pharmacokinetics of PPIs in cirrhotic patients. This evidence and data from the product information was reviewed by an expert panel who classified drugs as safe; no additional risks known; additional risks known; unsafe; or unknown...
April 24, 2018: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29131760/deep-learning-a-primer-for-radiologists
#3
REVIEW
Gabriel Chartrand, Phillip M Cheng, Eugene Vorontsov, Michal Drozdzal, Simon Turcotte, Christopher J Pal, Samuel Kadoury, An Tang
Deep learning is a class of machine learning methods that are gaining success and attracting interest in many domains, including computer vision, speech recognition, natural language processing, and playing games. Deep learning methods produce a mapping from raw inputs to desired outputs (eg, image classes). Unlike traditional machine learning methods, which require hand-engineered feature extraction from inputs, deep learning methods learn these features directly from data. With the advent of large datasets and increased computing power, these methods can produce models with exceptional performance...
November 2017: Radiographics: a Review Publication of the Radiological Society of North America, Inc
https://www.readbyqxmd.com/read/28916866/laparoscopic-versus-open-parenchymal-preserving-liver-resections-in-the-posterosuperior-segments-a-case-matched-study
#4
Mathieu D'Hondt, Esther Tamby, Isabelle Boscart, Simon Turcotte, Isabelle Parmentier, Hans Pottel, Réal Lapointe, Sander Ovaere, Franky Vansteenkiste, Franck Vandenbroucke-Menu
BACKGROUND: Patients with lesions in the posterosuperior (PS) segments of the liver have been considered poor candidates for laparoscopic liver resection (LLR). This study aims to compare short-term outcomes of LLR and open liver resections (OLR) in the PS segments. METHODS: This multicenter study consisted of all patients who underwent LLR in the PS segments and all patients who underwent OLR in the PS segments between October 2011 and July 2016. Laparoscopic cases were case-matched with those who had an identical open procedure during the same period based on tumor location (same segment) and the Brisbane classification of the resection...
March 2018: Surgical Endoscopy
https://www.readbyqxmd.com/read/28701219/excellent-local-control-and-tolerance-profile-after-stereotactic-body-radiotherapy-of-advanced-hepatocellular-carcinoma
#5
Eleni Gkika, Michael Schultheiss, Dominik Bettinger, Lars Maruschke, Hannes Philipp Neeff, Michaela Schulenburg, Sonja Adebahr, Simon Kirste, Ursula Nestle, Robert Thimme, Anca-Ligia Grosu, Thomas Baptist Brunner
BACKGROUND: To evaluate the efficacy and toxicity of stereotactic body radiotherapy (SBRT) in the treatment of advanced hepatocellular carcinoma (HCC). MATERIAL AND METHODS: Patients with large HCCs (median diameter 7 cm, IQR 5-10 cm) with a Child-Turcotte-Pugh (CTP) score A (60%) or B (40%) and Barcelona-Clinic Liver Cancer (BCLC) classification stage B or C were treated with 3 to 12 fractions to allow personalized treatment according to the size of the lesions and the proximity of the lesions to the organs at risk aiming to give high biologically equivalent doses assuming an α/β ratio of 10 Gy for HCC...
July 12, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28650354/prediction-of-hepatocellular-carcinoma-recurrence-beyond-milan-criteria-after-resection-validation-of-a-clinical-risk-score-in-an-international-cohort
#6
MULTICENTER STUDY
Jian Zheng, Joanne F Chou, Mithat Gönen, Neeta Vachharajani, William C Chapman, Maria B Majella Doyle, Simon Turcotte, Franck Vandenbroucke-Menu, Réal Lapointe, Stefan Buettner, Bas Groot Koerkamp, Jan N M Ijzermans, Chung Yip Chan, Brian K P Goh, Jin Yao Teo, Juinn Huar Kam, Prema R Jeyaraj, Peng Chung Cheow, Alexander Y F Chung, Pierce K H Chow, London L P J Ooi, Vinod P Balachandran, T Peter Kingham, Peter J Allen, Michael I D'Angelica, Ronald P DeMatteo, William R Jarnagin, Ser Yee Lee
OBJECTIVE: This study aims to validate a previously reported recurrence clinical risk score (CRS). SUMMARY OF BACKGROUND DATA: Salvage transplantation after hepatocellular carcinoma (HCC) resection is limited to patients who recur within Milan criteria (MC). Predicting recurrence patterns may guide treatment recommendations. METHODS: An international, multicenter cohort of R0 resected HCC patients were categorized by MC status at presentation...
October 2017: Annals of Surgery
https://www.readbyqxmd.com/read/28487614/patients-with-non-viral-liver-disease-have-a-greater-tumor-burden-and-less-curative-treatment-options-when-diagnosed-with-hepatocellular-carcinoma
#7
Waled Mohsen, Marcia Rodov, Emilia Prakoso, Barbara Charlton, David G Bowen, David J Koorey, Nicholas A Shackel, Geoffrey W McCaughan, Simone I Strasser
AIM: To assess the impact of underlying liver disease etiology on the presenting features and outcomes in a large cohort of patients with hepatocellular carcinoma (HCC). METHODS: A prospective database of all patients with HCC was established from 1998 to March 2012. One thousand and seventy-eight patients were categorized into three groups, based on the etiology of their liver disease: hepatitis B virus (HBV), hepatitis C virus (HCV) and non-viral liver disease (NVLD)...
April 21, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28486780/quantitative-proteomics-to-study-a-small-molecule-targeting-the-loss-of-von-hippel-lindau-in-renal-cell-carcinomas
#8
Nadia Bouhamdani, Andrew Joy, David Barnett, Kevin Cormier, Daniel Léger, Ian C Chute, Simon Lamarre, Rodney Ouellette, Sandra Turcotte
Inactivation of the tumor suppressor gene, von Hippel-Lindau (VHL), is known to play an important role in the development of sporadic clear cell renal cell carcinomas (ccRCCs). Even if available targeted therapies for metastatic RCCs (mRCCs) have helped to improve progression-free survival rates, they have no durable clinical response. We have previously shown the feasibility of specifically targeting the loss of VHL with the identification of a small molecule, STF-62247. Understanding its functionality is crucial for developing durable personalized therapeutic agents differing from those available targeting hypoxia inducible factor (HIF-) pathways...
August 15, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28422043/real-world-efficacy-and-safety-of-ritonavir-boosted-paritaprevir-ombitasvir-dasabuvir-%C3%A2-ribavirin-for-hepatitis-c-genotype-1-final-results-of-the-rev1tal-study
#9
John Lubel, Simone Strasser, Katherine A Stuart, Gregory Dore, Alexander Thompson, Stephen Pianko, Steven Bollipo, Joanne L Mitchell, Vincenzo Fragomeli, Tracey Jones, Sarah Chivers, Paul Gow, David Iser, Miriam Levy, Edmund Tse, Alessia Gazzola, Wendy Cheng, Saroj Nazareth, Sam Galhenage, Amanda Wade, Martin Weltman, Alan Wigg, Gerry MacQuillan, Joe Sasadeusz, Jacob George, Amany Zekry, Stuart K Roberts
BACKGROUND: Limited data exist on the outcomes of ritonavir-boosted paritaprevir with ombitasvir and dasabuvir (PrOD) ± ribavirin in a real-world setting. The aim of this study was to compare the efficacy and safety of PrOD-based therapy in hepatitis C genotype 1 patients with and without cirrhosis, and to explore pre-treatment factors predictive of sustained viral response (SVR) and serious adverse events (SAEs) on treatment. METHODS: 451 patients with hepatitis C genotype 1 treated in 20 centres across Australia were included...
2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28213791/tumor-associated-macrophage-infiltration-in-colorectal-cancer-liver-metastases-is-associated-with-better-outcome
#10
Michael J Cavnar, Simon Turcotte, Steven C Katz, Deborah Kuk, Mithat Gönen, Jinru Shia, Peter J Allen, Vinod P Balachandran, Michael I D'Angelica, T Peter Kingham, William R Jarnagin, Ronald P DeMatteo
BACKGROUND: Tumor-associated macrophages (TAMs) support growth in most human cancers, with the notable exception of colorectal adenocarcinoma, in which TAM infiltration of primary tumors is correlated with a better outcome. The importance of TAMs in colorectal liver metastases (CLM) is unknown. METHODS: Using a tissue microarray of CLM resected at their institution from 1998 to 2000, the authors quantified immune marker expression by immunohistochemistry (IHC) using Metamorph Image Analysis software...
July 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28026793/wireless-semg-based-body-machine-interface-for-assistive-technology-devices
#11
Cheikh Latyr Fall, Gabriel Gagnon-Turcotte, Jean-Francois Dube, Jean Simon Gagne, Yanick Delisle, Alexandre Campeau-Lecours, Clement Gosselin, Benoit Gosselin
Assistive technology (AT) tools and appliances are being more and more widely used and developed worldwide to improve the autonomy of people living with disabilities and ease the interaction with their environment. This paper describes an intuitive and wireless surface electromyography (sEMG) based body-machine interface for AT tools. Spinal cord injuries at C5-C8 levels affect patients' arms, forearms, hands, and fingers control. Thus, using classical AT control interfaces (keypads, joysticks, etc.) is often difficult or impossible...
July 2017: IEEE Journal of Biomedical and Health Informatics
https://www.readbyqxmd.com/read/27378611/a-health-at-every-size-intervention-improves-intuitive-eating-and-diet-quality-in-canadian-women
#12
Elise Carbonneau, Catherine Bégin, Simone Lemieux, Lyne Mongeau, Marie-Claude Paquette, Mylène Turcotte, Marie-Ève Labonté, Véronique Provencher
BACKGROUND & AIMS: Health at Every Size® (HAES® ) interventions focus on healthy lifestyle by promoting behavioral changes related to diet and physical activity while emphasizing self-acceptance and well-being through an empowerment and intuitive approach. The purpose of this study was to investigate the effects of a HAES® program on intuitive eating and diet quality in women. METHODS: The HAES® intervention, offered by professionals from Health and Social Services Centers in Quebec (Canada), was composed of thirteen 3-h weekly meetings and a 6-h intensive day...
June 2017: Clinical Nutrition: Official Journal of the European Society of Parenteral and Enteral Nutrition
https://www.readbyqxmd.com/read/27174990/histone-h3k36-mutations-promote-sarcomagenesis-through-altered-histone-methylation-landscape
#13
Chao Lu, Siddhant U Jain, Dominik Hoelper, Denise Bechet, Rosalynn C Molden, Leili Ran, Devan Murphy, Sriram Venneti, Meera Hameed, Bruce R Pawel, Jay S Wunder, Brendan C Dickson, Stefan M Lundgren, Krupa S Jani, Nicolas De Jay, Simon Papillon-Cavanagh, Irene L Andrulis, Sarah L Sawyer, David Grynspan, Robert E Turcotte, Javad Nadaf, Somayyeh Fahiminiyah, Tom W Muir, Jacek Majewski, Craig B Thompson, Ping Chi, Benjamin A Garcia, C David Allis, Nada Jabado, Peter W Lewis
Several types of pediatric cancers reportedly contain high-frequency missense mutations in histone H3, yet the underlying oncogenic mechanism remains poorly characterized. Here we report that the H3 lysine 36-to-methionine (H3K36M) mutation impairs the differentiation of mesenchymal progenitor cells and generates undifferentiated sarcoma in vivo. H3K36M mutant nucleosomes inhibit the enzymatic activities of several H3K36 methyltransferases. Depleting H3K36 methyltransferases, or expressing an H3K36I mutant that similarly inhibits H3K36 methylation, is sufficient to phenocopy the H3K36M mutation...
May 13, 2016: Science
https://www.readbyqxmd.com/read/26714499/the-dog-prostate-cancer-dpc-1-model-a-reliable-tool-for-molecular-imaging-of-prostate-tumors-and-metastases
#14
Simone Chevalier, Serge Moffett, Eric Turcotte, Murillo Luz, Lyne Chauvette, Vilma Derbekyan, Eleonora Scarlata, Fatima Zouanat, Armen G Aprikian, Maurice Anidjar
BACKGROUND: Clinical applicability of newly discovered reagents for molecular imaging is hampered by the lack of translational models. As the dog prostate cancer (DPC-1) model recapitulates in dogs the natural history of prostate cancer in man, we tested the feasibility of single-photon emission computed tomography (SPECT)/CT imaging in this model using an anti-prostate-specific membrane antigen (PSMA)/17G1 antibody as the radiotracer. METHODS: Immunoblots and immunohistochemistry (IHC) with 17G1 were performed on canine and human prostate cancer cell lines and tissues...
December 2015: EJNMMI Research
https://www.readbyqxmd.com/read/26516200/immunogenicity-of-somatic-mutations-in-human-gastrointestinal-cancers
#15
Eric Tran, Mojgan Ahmadzadeh, Yong-Chen Lu, Alena Gros, Simon Turcotte, Paul F Robbins, Jared J Gartner, Zhili Zheng, Yong F Li, Satyajit Ray, John R Wunderlich, Robert P Somerville, Steven A Rosenberg
It is unknown whether the human immune system frequently mounts a T cell response against mutations expressed by common epithelial cancers. Using a next-generation sequencing approach combined with high-throughput immunologic screening, we demonstrated that tumor-infiltrating lymphocytes (TILs) from 9 out of 10 patients with metastatic gastrointestinal cancers contained CD4(+) and/or CD8(+) T cells that recognized one to three neo-epitopes derived from somatic mutations expressed by the patient's own tumor...
December 11, 2015: Science
https://www.readbyqxmd.com/read/25600439/genetic-evidence-that-intratumoral-t-cell-proliferation-and-activation-are-associated-with-recurrence-and-survival-in-patients-with-resected-colorectal-liver-metastases
#16
Ajay V Maker, Hiromichi Ito, Qianxing Mo, Elliot Weisenberg, Li-Xuan Qin, Simon Turcotte, Shishir Maithel, Jinru Shia, Leslie Blumgart, Yuman Fong, William R Jarnagin, Ronald P DeMatteo, Michael I D'Angelica
Though immune responses correlate with prognosis in primary colorectal cancer, the role of tumor immunity in metastatic disease is less clear. We hypothesized that patient survival and tumor recurrence correlate with transcriptional evidence of lymphocyte proliferation/activation in resected colorectal cancer liver metastases (CRLM). Microarray gene analysis was performed on liver tumor specimens from 96 patients who underwent resection for CRLM. A Cox proportional hazards model identified genes associated with overall survival (OS) and recurrence-free survival (RFS)...
April 2015: Cancer Immunology Research
https://www.readbyqxmd.com/read/25018069/optimal-pancreatic-phase-delay-with-64-detector-ct-scanner-and-bolus-tracking-technique
#17
RANDOMIZED CONTROLLED TRIAL
An Tang, Jean-Sébastien Billiard, David-Olivier Chagnon, Fadi Rizk, Damien Olivié, Simon Turcotte, Miguel Chagnon, Luigi Lepanto
RATIONALE AND OBJECTIVES: To assess the optimal pancreatic phase delay in terms of parenchymal enhancement and tumor-to-pancreas contrast with a bolus-tracking method. MATERIALS AND METHODS: Patients referred for suspicion of pancreatic tumor and undergoing 64-detector computed tomography scanner were randomized to an individualized scan delay of 10, 20, or 30 seconds of nonionic contrast material (370 mg I/mL) after aortic enhancement above 150 Hounsfield units...
August 2014: Academic Radiology
https://www.readbyqxmd.com/read/24894090/tumor-mhc-class-i-expression-improves-the-prognostic-value-of-t-cell-density-in-resected-colorectal-liver-metastases
#18
Simon Turcotte, Steven C Katz, Jinru Shia, William R Jarnagin, T Peter Kingham, Peter J Allen, Yuman Fong, Michael I D'Angelica, Ronald P DeMatteo
Tumor-infiltrating lymphocytes (TIL) in colorectal cancer liver metastases (CLM) have been associated with more favorable patient outcomes, but whether MHC class I (MHC-I) expression on cancer cells affects prognosis is uncertain. Immunohistochemistry was performed on a tissue microarray of 158 patients with CLM, who underwent partial hepatectomy with curative intent. Using the antibody HC-10, which detects HLA-B and HLA-C antigens and a minority of HLA-A antigens, MHC-I expression was correlated with β-2 microglobulin (β2m; r = 0...
June 2014: Cancer Immunology Research
https://www.readbyqxmd.com/read/24812403/cancer-immunotherapy-based-on-mutation-specific-cd4-t-cells-in-a-patient-with-epithelial-cancer
#19
Eric Tran, Simon Turcotte, Alena Gros, Paul F Robbins, Yong-Chen Lu, Mark E Dudley, John R Wunderlich, Robert P Somerville, Katherine Hogan, Christian S Hinrichs, Maria R Parkhurst, James C Yang, Steven A Rosenberg
Limited evidence exists that humans mount a mutation-specific T cell response to epithelial cancers. We used a whole-exomic-sequencing-based approach to demonstrate that tumor-infiltrating lymphocytes (TIL) from a patient with metastatic cholangiocarcinoma contained CD4+ T helper 1 (T(H)1) cells recognizing a mutation in erbb2 interacting protein (ERBB2IP) expressed by the cancer. After adoptive transfer of TIL containing about 25% mutation-specific polyfunctional T(H)1 cells, the patient achieved a decrease in target lesions with prolonged stabilization of disease...
May 9, 2014: Science
https://www.readbyqxmd.com/read/24667641/pd-1-identifies-the-patient-specific-cd8%C3%A2-%C2%BA-tumor-reactive-repertoire-infiltrating-human-tumors
#20
Alena Gros, Paul F Robbins, Xin Yao, Yong F Li, Simon Turcotte, Eric Tran, John R Wunderlich, Arnold Mixon, Shawn Farid, Mark E Dudley, Ken-Ichi Hanada, Jorge R Almeida, Sam Darko, Daniel C Douek, James C Yang, Steven A Rosenberg
Adoptive transfer of tumor-infiltrating lymphocytes (TILs) can mediate regression of metastatic melanoma; however, TILs are a heterogeneous population, and there are no effective markers to specifically identify and select the repertoire of tumor-reactive and mutation-specific CD8⁺ lymphocytes. The lack of biomarkers limits the ability to study these cells and develop strategies to enhance clinical efficacy and extend this therapy to other malignancies. Here, we evaluated unique phenotypic traits of CD8⁺ TILs and TCR β chain (TCRβ) clonotypic frequency in melanoma tumors to identify patient-specific repertoires of tumor-reactive CD8⁺ lymphocytes...
May 2014: Journal of Clinical Investigation
keyword
keyword
83847
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"